Home / Categories / Miscellaneous / Samples / Sample ads
Click to view full size image
Click here for details on how to download this file to your desktop.

Pfizer

We've only scratched the surface on understanding the JAK/STAT pathway's role in atopic dermatitis (AD)

Key cytokines, including IL-4, IL-13, IL-22, IL-31, and TSLP, contribute to this chronic, relapsing-remitting inflammatory skin disease. Many of these cytokines are also thought to contribute to itch, a symptom responsible for much of the disease burden.

By inhibiting the JAK/STAT pathway, it may be possible to decrease signaling of key cytokines that drive AD inflammation, itch, and skin barrier disruption.

IL=interleukin; JAK=Janus kinase; STAT=signal transducer and activator of transcription; TSLP=thymic stromal lymphopoietin.

Let's explore more about the JAK/STAT pathway at scratchingtheADsurface.com

Pfizer

Pfizer does not currently have any JAK inhibitors approved for the treatment of AD.


References: 1. Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130 (6):1344-1354. 2. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70 (2):338-351. 3. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71 (2):327-349. 4. Katoh N, Ohya Y, Ikeda M, et al. Clinical practice guidelines for the management of atopic dermatitis 2018. J Dermatol. 2019;46 (12):1053-1101. 5. Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immunol. 2017;140 (3):633-643. 6. Hammarén HM, Virtanen AT, Raivola J, Silvennoinen O. The regulation of JAKS in cytokine signaling and its breakdown in disease. Cytokine. 2019;118:48-63.

PP-A2D-USA-0158-02 © 2020 Pfizer Inc. All rights reserved. December 2020

Country/Market: USA
Target: Healthcare Professional (HCP)
Size/duration: Single-page
Publication/Aired:
Dermatology Times - Vol 42 - No 3 - March 2021
Other ads from this brand
Rate this file (No vote yet)
About Subscriptions Contact us Twitter LinkedIn